Skip to main content

Month: January 2025

Chemung Financial Corporation Reports Annual Net Income of $23.7 million, or $4.96 per share, and Fourth Quarter 2024 Net Income of $5.9 million, or $1.24 per share

ELMIRA, N.Y., Jan. 28, 2025 (GLOBE NEWSWIRE) — Chemung Financial Corporation (the “Corporation”) (Nasdaq: CHMG), the parent company of Chemung Canal Trust Company (the “Bank”), today reported net income of $23.7 million, or $4.96 per share, for the year ended December 31, 2024, compared to $25.0 million, or $5.28 per share, for the year ended December 31, 2023. Net income was $5.9 million, or $1.24 per share, for the fourth quarter of 2024, compared to $5.7 million, or $1.19 per share, for the third quarter of 2024, and $3.8 million, or $0.80 per share, for the fourth quarter of 2023. “A prudent and relationship-based effort to manage funding costs provided a tailwind for fourth quarter earnings, and capped a solid year of results in an uncertain environment,” said Anders M. Tomson, President and CEO of Chemung Financial...

Continue reading

Stride Posts Record Quarterly Results

RESTON, Va., Jan. 28, 2025 (GLOBE NEWSWIRE) — Stride, Inc. (NYSE: LRN), one of the nation’s most successful technology-based education companies, today announced its results for the second fiscal quarter ended December 31, 2024. Second Quarter Fiscal 2025 Highlights Compared to 2024Revenue of $587.2 million, compared with $504.9 million. Income from operations of $125.1 million, compared with $84.3 million. Net income of $96.4 million, compared with $66.8 million. Diluted net income per share of $2.03, compared with $1.54. Adjusted operating income of $135.6 million, compared with $94.9 million. (1) Adjusted EBITDA of $160.4 million, compared with $118.3 million. (1)Second Quarter Fiscal 2025 Summary Financial Metrics  Three Months Ended December 31,   Change 2024/2023  2024   2023   $   %  (In thousands, except percentages...

Continue reading

Hanmi Financial Increases Cash Dividend 8% to $0.27 per share

LOS ANGELES, Jan. 28, 2025 (GLOBE NEWSWIRE) — Hanmi Financial Corporation (NASDAQ: HAFC, or “Hanmi”), the parent company of Hanmi Bank (the “Bank”), today announced that its Board of Directors declared a cash dividend on its common stock for the 2025 first quarter of $0.27 per share, up 8% from the prior quarter. The dividend will be paid on February 26, 2025, to stockholders of record as of the close of business on February 10, 2025. “Following another quarter of successful execution across our business, Hanmi is well positioned for continued success in 2025,” said Bonnie Lee, President and Chief Executive Officer. “The increase in our dividend reflects the Board’s confidence in Hanmi’s financial strength, relationship-driven banking model, and commitment to creating shareholder value.” About Hanmi Financial Corporation Headquartered...

Continue reading

Nokia Corporation: Repurchase of own shares on 28.01.2025

Nokia CorporationStock Exchange Release28 January 2025 at 22:30 EET Nokia Corporation: Repurchase of own shares on 28.01.2025 Espoo, Finland – On 28 January 2025 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 872,093 4.32CEUX – –BATE – –AQEU – –TQEX – –Total 872,093 4.32* Rounded to two decimals On 22 November 2024, Nokia announced that its Board of Directors is initiating a share buyback program to offset the dilutive effect of new Nokia shares issued to the shareholders of Infinera Corporation and certain Infinera Corporation share-based incentives. The repurchases in compliance with the Market Abuse Regulation (EU) 596/2014...

Continue reading

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

The grant funding will further Tevogen Bio’s mission to develop therapies for treatment of cancers and viral infections. Tevogen Bio may also utilize the grant funding to further expand its artificial intelligence effort. This grant is in addition to the previously announced $36 million loan agreement from 2Q24.WARREN, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, announced it may receive up to $10 million of non-dilutive grant funding. Tevogen Bio signed a grant agreement with KRHP LLC, receiving an initial contribution of $2 million. An additional $8 million may be contributed at a future date, contingent on KRHP LLC’s review of the Company’s activities. The grant is intended to further Tevogen Bio’s mission to...

Continue reading

Discount Doctor to Visit United Kingdom in Support of Investment Trusts

RYE, N.Y., Jan. 28, 2025 (GLOBE NEWSWIRE) — David Schachter, Senior Vice President of GAMCO Investors, Inc., will visit the United Kingdom to convey support for the British investment trust industry. With over 40 years of experience exclusively with retail, long term, closed-end fund investors, Mr. Schachter, a most senior and experienced veteran of the U.S. Closed End Fund industry, was recently given the title of Discount Doctor by the Trustees of The GAMCO Natural Resources, Gold & Income Trust (GNT), which trades on the NYSE. Mr. Schachter said, “The way I see it, the United States owes a debt to the British Investment Trust Industry, which helped build our railroads in the 1800s. Last week in his inauguration speech, President Trump spoke of America’s achievements stating, ‘In America, the impossible is what we do best…Together...

Continue reading

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 19,685,040 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 19,685,040 shares of common stock in a registered direct offering (the “Offering”) at a combined purchase price of $1.27 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $1.20 per share, will be immediately exercisable...

Continue reading

DIAGNOS to Present at The Microcap Conference 2025

BROSSARD, Quebec, Jan. 28, 2025 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. Details of the presentation:Event: The Microcap ConferenceDate and Time: January 29, 2025, at 4:30 p.m., ETLocation: Borgata Hotel Casino & Spa, Studio C, Atlantic City, NJPresenter: André Larente, Chief Executive OfficerDIAGNOS will engage in one-on-one meetings with institutional and individual...

Continue reading

Christian Dior : Christian Dior achieves a solid performance despite an unfavorable global economic environment

Christian Dior achieves a solid performance despite an unfavorable global economic environment . Revenue: €84.7 billion. Profit from recurring operations: €19.6 billion. Free cash flow: €10.5 billion. Acceleration in the fourth quarter, driven by Asia, the United States and Europe. Major economic and social impact of the Group in France and around the world Paris, January 28, 2025 The Christian Dior group recorded revenue of €84.7 billion in 2024. Growth continued (+1% on an organic basis) despite a challenging economic and geopolitical environment, as well as a high basis of comparison following several years of exceptional post-Covid growth. Europe and the United States posted growth on a constant consolidation scope and currency basis; Japan saw double-digit revenue growth; the rest of Asia reflected the strong growth in spending by...

Continue reading

C&F Financial Corporation Announces Net Income for 2024

TOANO, Va., Jan. 28, 2025 (GLOBE NEWSWIRE) — C&F Financial Corporation (the Corporation) (NASDAQ: CFFI), the holding company for C&F Bank, today reported consolidated net income of $6.0 million for the fourth quarter of 2024, compared to $5.1 million for the fourth quarter of 2023. The Corporation reported consolidated net income of $19.9 million for the year ended December 31, 2024, compared to $23.7 million for the year ended December 31, 2023. The following table presents selected financial performance highlights for the periods indicated:                                   For The Quarter Ended   For the Year Ended  Consolidated Financial Highlights (unaudited)   12/31/2024     12/31/2023   12/31/2024     12/31/2023  Consolidated net income (000’s)   $ 6,029     $ 5,088   $ 19,918     $ 23,746                                 Earnings...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.